ImmunoGen — FY2016 Earnings Presentation
22 slides from ImmunoGen's earnings presentation, Aug 4, 2016
Slide 1: Carol Hausner, Investor Relations & Corporate Communications
Executive Director, Investor Relations & Corporate Communications Carol Hausner 2
Slide 2: Forward-Looking Statements
These slides include forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the occurrence, timing and outcome of potential pre-clinical, clinical and regulatory events related to the Company's and
Slide 3: President and Chief Executive Officer Mark Enyedy
President and Chief Executive Officer Mark Enyedy 4
Slide 4: ImmunoGen Today: Positioned for Sustainable Value Creation
ImmunoGen Today: Positioned for Sustainable Value Creation 5 Leadership in antibody-drug conjugates (ADCs) Lead program entering Phase 3 before year end Platform generating novel clinical candidates Technology validated clinically and through partnerships Strong cash position Experienced management
Slide 5: Strategic Direction & Priorities
Strategic Direction & Priorities 6 Platinum-resistant ovarian cancer Execute on speed-to-market for mirvetuximab soravtansine IMGN779, IMGN632, IMGN529 Accelerate earlier-stage portfolio Payloads, linkers, methods of conjugation Continue to drive innovation in ADCs as cancer therapies Lever partners
Slide 6: Leadership in ADCs Building Momentum
Leadership in ADCs Building Momentum ImmunoGen Programs Preclinical Phase 1 Phase 2 Recent Achievements Mirvetuximab soravtansine Ovarian - monotherapy Met with FDA; Advancing to Phase 3 Ovarian - combination Opened Avastin® Phase 2 cohort IMGN529 DLBCL - combination Initiated Phase 2 Coltuximab rav
Slide 7: Driving ADC Innovations that Produce Results
8 Driving ADC Innovations that Produce Results Our Competitive Advantage The most comprehensive, validated technology portfolio in the industry Linkers Payloads Conjugation Clinical Validation Ongoing Non-cleavable Tubulin-acting DM1 Lysine Kadcyla® Approved, survival benefit (EMILIA) Herceptin-inse
Slide 8: Lever Partnerships to Expand Impact of Innovations
Lever Partnerships to Expand Impact of Innovations Enabling Our Technology to Benefit More Patients Partner Programs (active, disclosed) Phase 1 Phase 2 Phase 3 Marketed KADCYLA Anetumab ravtansine Indatuximab ravtansine Isatuximab SAR566658 SAR408701 SAR428926 AMG XXX PCA062 LY3076226 CX-2009 LY307
Slide 9: EVP and Chief Development Officer Dr. Charles Morris
EVP and Chief Development Officer Dr. Charles Morris 10
Slide 10: Execute on Speed-to-Market for Lead Program Mirvetuximab Soravtansine
Execute on Speed-to-Market for Lead Program Mirvetuximab Soravtansine 11 First ADC to enter registration testing for ovarian cancer MOA distinct from other approaches (PARPs, I/Os, Avastin ) Different clinical profile 1WHO GLOBOCAN 2012, ACS Cancer Facts and Figures. 2Published data and prescribing
Slide 11: Mirvetuximab Soravtansine Ready for Phase 3
Mirvetuximab Soravtansine Ready for Phase 3 12 Data presented at ASCO 2016 (abstract #5567) Tumor cells with 2+/3+ FRα expression High: at least 75%; Medium: 50-74%; Low: 25-49% Positive meeting with FDA Sizeable safety database Single-agent activity Defined population ≤5 prior regimens ≥ low FRα ≤3
Slide 12: Mirvetuximab Soravtansine FORWARD I Phase 3 Trial
Mirvetuximab Soravtansine FORWARD I Phase 3 Trial 13 Mirvetuximab soravtansine Physician’s choice single agent chemo* with platinum-resistant ovarian cancer treated with up to 3 prior regimens; high or medium FRα levels *Pegylated liposomal doxorubicin (PLD), topotecan, weekly paclitaxel. 333 patien
Slide 13: Mirvetuximab Soravtansine FORWARD II: Expanding for Ovarian Cancer
Mirvetuximab Soravtansine FORWARD II: Expanding for Ovarian Cancer 14 Platinum-based regimen Potential for Avastin+paclitaxel Once platinum-resistant Single agent chemotherapy Recurrence Treatment paradigm in US Phase 1/2 trial, Combination regimens to benefit more patients, longer Registration tria
Slide 14: Mirvetuximab Soravtansine Combination Regimens in Ovarian Cancer
+ PLD Extensive use for ovarian cancer Mirvetuximab Soravtansine Combination Regimens in Ovarian Cancer 15 ClinicalTrials.gov identifier: NCT02606305 PLD = pegylated liposomal doxorubicin Keytruda® is a registered trademark of Merck & Co., Inc. Patients with FRα-positive ovarian cancer + Avastin Sta
Slide 15: Accelerate Earlier-Stage Portfolio Clinical Trials Initiated
Accelerate Earlier-Stage Portfolio 2 Clinical Trials Initiated 16 Targets CD33; deploys lead IGN Phase 1 testing initiated 2Q2016 IMGN779 – New Class of ADC for AML IMGN529 – Striking Synergy with Rituxan Preclinically ASH 2015 abstract #1548; ICML 2015 abstract P-274 Rituxan® is a registered tradem
Slide 16: EVP and Chief Financial Officer David Johnston
EVP and Chief Financial Officer David Johnston 17
Slide 17: Financials
Financials *FY2015 includes $20 MM upfront payment from Takeda technology access agreement. **FY2015 includes approx. $194 MM net proceeds from Kadcyla royalty monetization transaction received April 2015. FY2016 includes approx. $97 MM net proceeds from $100 MM convertible debt financing in June 20
Slide 18: President and Chief Executive Officer Mark Enyedy
President and Chief Executive Officer Mark Enyedy 19
Slide 19: Anticipated Events
Mirvetuximab soravtansine FORWARD I registration trial Meet with FDA ( ) Initiation (4Q2016) FORWARD II Phase 1b/2 Avastin expansion cohort open ( ) Keytruda cohort open (3Q2016) First data (2Q2017) Earlier-stage portfolio IMGN779 Phase 1 initiation ( ) First clinical data (2017) IMGN632 – preclinic
Slide 20: ImmunoGen Today: Positioned for Sustainable Value Creation
ImmunoGen Today: Positioned for Sustainable Value Creation 21 Cutting edge technology in growing field Rich pipeline of differentiated product candidates Enhanced financial resources Experienced team Strong partnerships
Slide 21: ImmunoGen Today: Positioned for Sustainable Value Creation
ImmunoGen Today: Cutting edge technology in growing field Positioned for Sustainable . Rich pipeline of differentiated product candidates Value Creation Enhanced financial resources Strong partnerships IMMUNOGEN
Slide 22: Q&A
Q&A Carol Hausner IMMUNOGEN